PTP4A2 and acute myeloid leukemia: FLT3 mutations are one of the more common AML-associated lesions, and using ectopic FLT3-ITD cell lines, in both in vitro and in vivo transplantation studies, it was demonstrated that PRL2 inhibition reduced AML burden in these FLT3-driven AMLs (49).